SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Tove Henriksen, Clinical insights into use of apomorphine in Parkinson's disease: tools for clinicians, Neurodegenerative Disease Management, 2014, 4, 3, 271

    CrossRef

  2. 2
    Karoline Wenzel, Carl Nikolaus Homann, Giovanni Fabbrini, Carlo Colosimo, The role of subcutaneous infusion of apomorphine in Parkinson’s disease, Expert Review of Neurotherapeutics, 2014, 14, 7, 833

    CrossRef

  3. 3
    Mensikova Katerina, Kaiserova Michaela, Vastik Miroslav, Kurcova Sandra, Kanovsky Petr, Treatment of camptocormia with continuous subcutaneous infusions of apomorphine: 1-year prospective pilot study, Journal of Neural Transmission, 2014,

    CrossRef

  4. 4
    Olivier Rascol, Susan Fox, Fabrizio Gasparini, Christopher Kenney, Thérèse Di Paolo, Baltazar Gomez-Mancilla, Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias, Parkinsonism & Related Disorders, 2014, 20, 9, 947

    CrossRef

  5. 5
    Monika Pötter-Nerger, Peter Ludewig, Ute Hidding, Ines Goerendt, Christian Gerloff, Carsten Buhmann, Wann sind Pflaster, Pens oder Pumpen eine sinnvolle Ergänzung zur oralen Therapie?, InFo Neurologie & Psychiatrie, 2014, 16, 12, 42

    CrossRef

  6. 6
    J. Kulisevsky, M.R. Luquin, J.M. Arbelo, J.A. Burguera, F. Carrillo, A. Castro, J. Chacón, P.J. García-Ruiz, E. Lezcano, P. Mir, J.C. Martinez-Castrillo, I. Martínez-Torres, V. Puente, Á. Sesar, F. Valldeoriola-Serra, R. Yañez, Advanced Parkinson's disease: Clinical characteristics and treatment. Part II, Neurología (English Edition), 2013, 28, 9, 558

    CrossRef

  7. 7
    Andrzej Bogucki, Apomorfina w zaawansowanej chorobie Parkinsona, Neurologia i Neurochirurgia Polska, 2013, 47, 5, 476

    CrossRef

  8. 8
    J. Kulisevsky, M.R. Luquin, J.M. Arbelo, J.A. Burguera, F. Carrillo, A. Castro, J. Chacón, P.J. García-Ruiz, E. Lezcano, P. Mir, J.C. Martinez-Castrillo, I. Martínez-Torres, V. Puente, Á. Sesar, F. Valldeoriola-Serra, R. Yañez, Enfermedad de Parkinson avanzada. Características clínicas y tratamiento. Parte II, Neurología, 2013, 28, 9, 558

    CrossRef

  9. 9
    Francisco Grandas, Subcutaneous infusions of apomorphine: a reappraisal of its therapeutic efficacy in advanced Parkinson’s disease, Expert Review of Neurotherapeutics, 2013, 13, 12, 1343

    CrossRef

  10. You have free access to this content10
    J. J. Ferreira, R. Katzenschlager, B. R. Bloem, U. Bonuccelli, D. Burn, G. Deuschl, E. Dietrichs, G. Fabbrini, A. Friedman, P. Kanovsky, V. Kostic, A. Nieuwboer, P. Odin, W. Poewe, O. Rascol, C. Sampaio, M. Schüpbach, E. Tolosa, C. Trenkwalder, A. Schapira, A. Berardelli, W. H. Oertel, Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease, European Journal of Neurology, 2013, 20, 1
  11. 11
    Angelo Antonini, Ioannis U. Isaias, Giorgia Rodolfi, Andrea Landi, Francesca Natuzzi, Chiara Siri, Gianni Pezzoli, A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation, Journal of Neurology, 2011, 258, 4, 579

    CrossRef

  12. 12
    Mildred D. Gottwald, Michael J. Aminoff, Therapies for dopaminergic-induced dyskinesias in parkinson disease, Annals of Neurology, 2011, 69, 6
  13. 13
    S. Thobois, E. Broussolle, M. Aya Kombo, P. Pollak, P. Krack, Reply: Dopamine agonist withdrawal syndrome and non-motor symptoms after Parkinson's disease surgery, Brain, 2010, 133, 11, e156

    CrossRef

  14. 14
    Mark Stacy, Medical Treatment of Parkinson Disease, Neurologic Clinics, 2009, 27, 3, 605

    CrossRef

  15. 15
    M. Steiger, Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease, European Journal of Neurology, 2008, 15, 1
  16. 16
    Pedro J. García Ruiz, Ángel Sesar Ignacio, Begoña Ares Pensado, Alfonso Castro García, Fernando Alonso Frech, Mercedes Álvarez López, José Arbelo González, Joan Baiges Octavio, Juan Andrés Burguera Hernández, Matilde Calopa Garriga, Dulce Campos Blanco, Belén Castaño García, Manuel Carballo Cordero, José Chacón Peña, Anna Espino Ibáñez, Aránzazu Gorospe Onisalde, Santiago Giménez-Roldán, Pilar Granés Ibáñez, Jorge Hernández Vara, Ramón Ibáñez Alonso, Félix Javier Jiménez Jiménez, Jerzy Krupinski, Jaime Kulisevsky Bojarsky, Inés Legarda Ramírez, Elena Lezcano García, Juan Carlos Martínez-Castrillo, Dolores Mateo González, Francesc Miquel Rodríguez, Pablo Mir, Elena Muñoz Fargas, José Obeso Inchausti, Jesús Olivares Romero, José Olivé Plana, Pilar Otermin Vallejo, Berta Pascual Sedano, Víctor Pérez de Colosía Rama, Isabel Pérez López-Fraile, Albert Planas Comes, Víctor Puente Periz, María Cruz Rodríguez Oroz, Dolores Sevillano García, Pilar Solís Pérez, José Suárez Muñoz, Julia Vaamonde Gamo, Caridad Valero Merino, Francesc Valldeoriola Serra, José Miguel Velázquez Pérez, Rosa Yáñez Baña, Ivana Zamarbide Capdepon, Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: A multicenter study, Movement Disorders, 2008, 23, 8
  17. 17
    S. Lal, J. X. Thavundayil, N. M. K. Ng Ying Kin, X. Dai, G. Schwartz, A. Montoya, Induction of tolerance of dopaminergic responses in man, Journal of Neural Transmission, 2008, 115, 8, 1189

    CrossRef

  18. 18
    Mark Stacy, Andrew Galbreath, Optimizing Long-Term Therapy for Parkinson Disease, Clinical Neuropharmacology, 2008, 31, 2, 120

    CrossRef

  19. 19
    Angelo Antonini, Continuous dopaminergic stimulation—From theory to clinical practice, Parkinsonism & Related Disorders, 2007, 13, S24

    CrossRef

  20. 20
    John G. Nutt, Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?, Movement Disorders, 2007, 22, 1
  21. 21
    Michael J. Jackson, Lance A. Smith, Ghassan Al-Barghouthy, Sarah Rose, Peter Jenner, Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets, Experimental Neurology, 2007, 204, 1, 162

    CrossRef

  22. 22
    Drew S. Kern, Rajeev Kumar, Deep Brain Stimulation, The Neurologist, 2007, 13, 5, 237

    CrossRef

  23. 23
    Brad J. Kolls, Mark Stacy, Apomorphine, Clinical Neuropharmacology, 2006, 29, 5, 292

    CrossRef

  24. 24
    Wendy M. Ingram, Melanie J. Priston, Graham J. Sewell, Improved assay for R(−)-apomorphine with application to clinical pharmacokinetic studies in Parkinson's disease, Journal of Chromatography B, 2006, 831, 1-2, 1

    CrossRef

  25. 25
    S. Drapier, M. Vérin, L’apomorphine en perfusion sous-cutanée continue dans le traitement de la maladie de Parkinson, Revue Neurologique, 2006, 162, 10, 1019

    CrossRef

  26. You have free access to this content26
    M. Horstink, E. Tolosa, U. Bonuccelli, G. Deuschl, A. Friedman, P. Kanovsky, J. P. Larsen, A. Lees, W. Oertel, W. Poewe, O. Rascol, C. Sampaio, Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease, European Journal of Neurology, 2006, 13, 11
  27. 27
    D. Dressler, Apomorphin bei der Behandlung des Morbus Parkinson, Der Nervenarzt, 2005, 76, 6, 681

    CrossRef

  28. 28
    Brad J Kolls, Mark Stacy, Apomorphine: an overview of clinical use, Aging Health, 2005, 1, 2, 193

    CrossRef

  29. 29
    Regina Katzenschlager, Andrew Hughes, Andrew Evans, Alice J. Manson, Marion Hoffman, Lesley Swinn, Hilary Watt, Kailash Bhatia, Niall Quinn, Andrew J. Lees, Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: A prospective study using single-dose challenges, Movement Disorders, 2005, 20, 2
  30. 30
    Dirk Deleu, Yolande Hanssens, Margaret G Northway, Subcutaneous Apomorphine, Drugs & Aging, 2004, 21, 11, 687

    CrossRef

  31. 31
    John G. Nutt, Long-term l-DOPA therapy: challenges to our understanding and for the care of people with Parkinson's disease, Experimental Neurology, 2003, 184, 1, 9

    CrossRef

  32. 32
    Alice J. Manson, Kirsten Turner, Andrew J. Lees, Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: Long-term follow-up study of 64 patients, Movement Disorders, 2002, 17, 6
  33. 33
    W. H. Oertel, A. Berardelli, B. R. Bloem, U. Bonuccelli, D. Burn, G. Deuschl, E. Dietrichs, G. Fabbrini, J. J. Ferreira, A. Friedman, P. Kanovsky, V. Kostic, A. Nieuwboer, P. Odin, W. Poewe, O. Rascol, C. Sampaio, M. Schüpbach, E. Tolosa, C. Trenkwalder, Late (Complicated) Parkinson's Disease,